Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

Benzinga · 10/25 11:00
Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.